Drug Profile


Alternative Names: Incivek; Incivo; LY-570310; MP-424; Telavic; VX-950

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Eli Lilly; Vertex Pharmaceuticals
  • Developer Janssen R&D Ireland; Mitsubishi Tanabe Pharma Corporation; Vertex Pharmaceuticals
  • Class Antivirals; Cyclohexanes; Cyclopentanes; Cyclopropanes; Peptidomimetics; Pyrazines; Pyrrolidines; Small molecules
  • Mechanism of Action Hepatitis C virus NS3 protein inhibitors; Hepatitis C virus NS4 protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Hepatitis C

Most Recent Events

  • 03 Aug 2017 No recent reports on development identified - Registered for Hepatitis C in Taiwan (PO)
  • 01 Aug 2017 Discontinued - Phase-I/II for Hepatitis C (Combination therapy, In adolescents, In children) in USA, Italy, Spain, Belgium, Germany and United Kingdom (PO), because not listed on Vertex and Janssen Pharmaceutica pipeline, August 2017
  • 07 Jun 2016 Vertex terminates a phase I/II trial in Hepatitis C (Combination therapy, In adolescents, In children) in USA, United Kingdom, Belgium, Germany, Italy and Spain (NCT01701063)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top